A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab
NCT07454889
·
clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Hidradenitis Suppurativa
Sponsor
Novartis Pharmaceuticals